JP2009085759A - 固形癌の検査方法 - Google Patents
固形癌の検査方法 Download PDFInfo
- Publication number
- JP2009085759A JP2009085759A JP2007255497A JP2007255497A JP2009085759A JP 2009085759 A JP2009085759 A JP 2009085759A JP 2007255497 A JP2007255497 A JP 2007255497A JP 2007255497 A JP2007255497 A JP 2007255497A JP 2009085759 A JP2009085759 A JP 2009085759A
- Authority
- JP
- Japan
- Prior art keywords
- urine
- cancer
- antibody
- alpha
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 76
- 201000011510 cancer Diseases 0.000 title claims abstract description 63
- 239000007787 solid Substances 0.000 title claims abstract description 49
- 238000012360 testing method Methods 0.000 title claims abstract description 34
- 210000002700 urine Anatomy 0.000 claims abstract description 109
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims abstract description 21
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims abstract description 13
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 32
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 17
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 14
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 238000010998 test method Methods 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 238000007689 inspection Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 239000002033 PVDF binder Substances 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108010091212 pepstatin Proteins 0.000 description 5
- 229950000964 pepstatin Drugs 0.000 description 5
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- GNNALEGJVYVIIH-UHFFFAOYSA-N benzene-1,2-diamine;hydrochloride Chemical compound Cl.NC1=CC=CC=C1N GNNALEGJVYVIIH-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VZDUALONEGFMEQ-UHFFFAOYSA-L disodium (4-nitrophenyl) phosphate hydrate Chemical compound O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VZDUALONEGFMEQ-UHFFFAOYSA-L 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000017744 gonadal teratoma Diseases 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
【解決手段】本発明は、分子量52KDaのα1−アンチトリプシン(α1−AT52)が尿中に検出された場合に固形癌に罹患していると判定する、固形癌の検査方法を提供する。
【選択図】なし
Description
まず、血漿由来のヒトα1−AT52の標品タンパク質(CALBIOCHEM社製)をD−PBS(−)に溶解した抗原液(60μg/0.3mL)にフロイント完全アジュバント(FCA;DIFCO社)を1:1(v/v)の割合で加え、2本のガラス製注射器を用いて十分に乳濁化し、抗原とアジュバントを含む乳濁液を調製した。
まず、1)で抗ヒトα1−AT52抗体の抗原タンパク質として用いたヒトα1−AT52の標品タンパク質(CALBIOCHEM社製)の分子量を、ドデシル硫酸ナトリウム・ポリアクリルアミド電気泳動(SDS−PAGE)で確認した。
固形癌患者の尿には健常人の尿に含まれない分子量52kDaのタンパク質が存在することが予備実験で明らかとなっていたため、このタンパク質がα1−AT52であるかどうかについて、抗ヒトα1−AT52抗体を用いたウェスタンブロッティング法で調べた。
子宮癌患者(50歳代女性、肺転移有り)より採取した尿サンプルを、以下の3種類の条件で調製及び保存し、尿中のα1−AT52の検出に及ぼす影響について調べた。
・条件1:尿を採取後直ちに氷冷し、3,000×g、4℃で10分間、遠心分離を行い、その上清を回収した。回収した上清は、その後直ちに−85℃の冷凍庫で保存した。
・条件2:尿を採取後直ちに室温(28℃)で6時間放置し、3,000×g、4℃で10分間、遠心分離を行い、その上清を回収した。回収した上清は、その後直ちに−85℃の冷凍庫で保存した。
・条件3:尿を採取後直ちにプロテアーゼ阻害剤であるコンプリート(Complete;ロシュ・ダイアグノスティックス社製)及びペプスタチン(Pepstatin;ロシュ・ダイアグノスティックス社製)を添加した。コンプリートは、1錠/2mL(水溶解)のストック溶液を調製し、その16μLを400μLの尿サンプルに添加し、ペプスタチンは、1mg/mL(MeOH溶解)のストック溶液を調製し、さらにMeOHで10倍に希釈し、その2.8μLを400μLの尿サンプルに添加した。プロテアーゼ阻害剤の添加後、尿サンプルを室温で6時間放置し、3,000×g、4℃で10分間、遠心分離を行い、その上清を回収した。回収した上清は、その後直ちに−85℃の冷凍庫に保存した。
Claims (7)
- 分子量52KDaのα1−アンチトリプシンが尿中に検出された場合に固形癌に罹患していると判定する、固形癌の検査方法。
- 被験者から採取された尿を凍結乾燥して凍結乾燥尿を得る凍結乾燥ステップと、
前記凍結乾燥尿中に分子量52KDaのα1−アンチトリプシンが検出された場合に固形癌に罹患していると判定する判定ステップと、
を備える、請求項1記載の検査方法。 - 被験者から採取された尿に有効量のプロテアーゼインヒビターを添加する添加ステップと、
プロテアーゼインヒビターを添加した前記尿中に分子量52KDaのα1−アンチトリプシンが検出された場合に固形癌に罹患していると判定する判定ステップと、
を備える、請求項1記載の検査方法。 - 前記α1−アンチトリプシンは、抗α1−アンチトリプシン抗体又はその機能的断片に結合する性質を利用して検出される、請求項1〜3のいずれか一項記載の検査方法。
- 前記抗α1−アンチトリプシン抗体は、ハイブリドーマ16C2(FERM ABP−10909)が生産する抗体である、請求項4記載の検査方法。
- 前記固形癌は、大腸癌、胃癌又は食道癌である、請求項1〜5のいずれか一項記載の検査方法。
- 請求項1〜6記載の検査方法を用いて固形癌の検査を行うための検査キットであって、ハイブリドーマ16C2(FERM ABP−10909)が生産する抗体を含む、検査キット。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007255497A JP4916409B2 (ja) | 2007-09-28 | 2007-09-28 | 固形癌の検査方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007255497A JP4916409B2 (ja) | 2007-09-28 | 2007-09-28 | 固形癌の検査方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009085759A true JP2009085759A (ja) | 2009-04-23 |
JP4916409B2 JP4916409B2 (ja) | 2012-04-11 |
Family
ID=40659369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007255497A Active JP4916409B2 (ja) | 2007-09-28 | 2007-09-28 | 固形癌の検査方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4916409B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015169608A (ja) * | 2014-03-10 | 2015-09-28 | 浜松ホトニクス株式会社 | 癌の検査方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0390081A (ja) * | 1989-09-02 | 1991-04-16 | Fujita Gakuen | ビオプテリン,ネオプテリン及び天然プテリジンの酵素免疫測定法及びそのための支持体 |
JPH03127800A (ja) * | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
WO2000039583A1 (fr) * | 1998-12-28 | 2000-07-06 | Kabushiki Kaisya Advance | Système d'identification de micro-organismes |
WO2005040222A1 (en) * | 2003-10-16 | 2005-05-06 | Bayer Healthcare Llc | Monoclonal antibodies for detection of urinary trypsin inhibitors |
WO2006121892A2 (en) * | 2005-05-05 | 2006-11-16 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Diagnosis of liver pathology through assessment of protein glycosylation |
WO2007076439A2 (en) * | 2005-12-22 | 2007-07-05 | Abbott Laboratories | Methods and marker combinations for screening for predisposition to lung cancer |
-
2007
- 2007-09-28 JP JP2007255497A patent/JP4916409B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0390081A (ja) * | 1989-09-02 | 1991-04-16 | Fujita Gakuen | ビオプテリン,ネオプテリン及び天然プテリジンの酵素免疫測定法及びそのための支持体 |
JPH03127800A (ja) * | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
WO2000039583A1 (fr) * | 1998-12-28 | 2000-07-06 | Kabushiki Kaisya Advance | Système d'identification de micro-organismes |
WO2005040222A1 (en) * | 2003-10-16 | 2005-05-06 | Bayer Healthcare Llc | Monoclonal antibodies for detection of urinary trypsin inhibitors |
WO2006121892A2 (en) * | 2005-05-05 | 2006-11-16 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Diagnosis of liver pathology through assessment of protein glycosylation |
JP2008541060A (ja) * | 2005-05-05 | 2008-11-20 | フィラデルフィア ヘルス アンド エデュケーション コーポレーション ディー/ビー/エー ドレクセル ユニバーシティー カレッジ オブ メディシン | タンパク質のグリコシル化の評価による肝臓病変の診断 |
WO2007076439A2 (en) * | 2005-12-22 | 2007-07-05 | Abbott Laboratories | Methods and marker combinations for screening for predisposition to lung cancer |
JP2009521692A (ja) * | 2005-12-22 | 2009-06-04 | アボット・ラボラトリーズ | 肺がんへの傾向についてのスクリーニングのための方法およびマーカー組合せ |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015169608A (ja) * | 2014-03-10 | 2015-09-28 | 浜松ホトニクス株式会社 | 癌の検査方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4916409B2 (ja) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2799876B1 (en) | Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers | |
RU2693006C2 (ru) | Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы | |
EP2239576A1 (en) | Composition and method for diagnosis or detection of gastric cancer | |
JP7317379B2 (ja) | 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法 | |
US20100041167A1 (en) | Drug for diagnosing large intestinal cancer and/or polyp, observing postoperative course and monitoring recurrence | |
CN108027367A (zh) | 基于pla2r1表位谱和扩散分析的膜性肾病的预后和监测 | |
JP5322556B2 (ja) | 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法 | |
EP1295127B1 (en) | Inter-alpha-trypsin as a marker for sepsis | |
JP5670422B2 (ja) | 胃癌検出用マーカー及び胃癌検出方法 | |
US20170153239A1 (en) | Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer | |
US20120107295A1 (en) | Methods and Compositions for Detecting Pancreatic Disease | |
JP5773979B2 (ja) | 胃癌検出用マーカー及び胃癌検出方法 | |
JP7449530B2 (ja) | 腎癌の検出方法及び検査薬 | |
JP4916409B2 (ja) | 固形癌の検査方法 | |
WO2020241617A1 (ja) | 抗ヒトハプトグロビン抗体、及びこれを用いた炎症性腸疾患の判定方法 | |
JP2014115186A (ja) | 胃癌、肺癌及び/又は食道癌の検出方法 | |
JP2009168669A (ja) | 胃癌の診断又は検出のための組成物及び方法 | |
JP7509361B2 (ja) | 炎症性腸疾患の診断を補助する方法 | |
WO2021246153A1 (ja) | 膵臓がんの検出方法及び検出試薬 | |
KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
US9229012B2 (en) | Specific A1AT monoclonal antibodies for detection of endometriosis | |
JP2012018119A (ja) | 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法 | |
JP2022083307A (ja) | 卵巣がんの診断を補助する方法 | |
WO2013176070A1 (ja) | 癌の検出方法 | |
JP2014115188A (ja) | 胃癌、膵癌、肺癌及び/又は食道癌の検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100426 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120117 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120124 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150203 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4916409 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |